-
Je něco špatně v tomto záznamu ?
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
MA. Thompson, M. Boccadoro, X. Leleu, J. Vela-Ojeda, F. van Rhee, KC. Weisel, RM. Rifkin, SZ. Usmani, R. Hájek, G. Cook, R. Abonour, M. Armour, KE. Morgan, SP. Yeh, CL. Costello, JG. Berdeja, FE. Davies, JA. Zonder, HC. Lee, J. Omel, A. Spencer,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- chřipka lidská * prevence a kontrola MeSH
- hospitalizace MeSH
- lidé MeSH
- mnohočetný myelom * MeSH
- prospektivní studie MeSH
- vakcinace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. MATERIALS AND METHODS: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. RESULTS: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. CONCLUSION: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www. CLINICALTRIALS: gov as #NCT02761187.
1st Affiliated Hospital Soochow University Suzhou Jiangsu P R China
Aurora Cancer Care Advocate Aurora Research Institute Advocate Aurora Health Milwaukee WI
China Medical University Hospital Taichung City P R China
Department of Hematology Clinica São Germano and Santa Casa Medical School São Paulo Brazil
Department of Hematology Oncology Mount Sinai School of Medicine New York NY
Department of Hematology Tennessee Oncology and Sarah Cannon Research Institute Nashville TN
Department of Lymphoma and Myeloma The University of Texas M D Anderson Cancer Center Houston TX
Division of Hematology University of Torino Torino Italy
Hematology Department Hospital Universitario de Salamanca CIBERONC Salamanca Spain
Indiana University School of Medicine Indianapolis IN
Leeds Cancer Centre Leeds Teaching Hospitals Trust Leeds UK
Levine Cancer Institute Charlotte NC
Mijelom CRO Croatian Myeloma Support Association Zagreb Croatia
Myeloma Patients Europe Brussels Belgium
Perlmutter Cancer Center NYU Langone New York NY
Pôle Régional de Cancérologie Department of Hematology CHU La Milétrie Poitiers Poitiers France
Rocky Mountain Cancer Centers US Oncology Research Denver CO
Takeda Development Center Americas Inc Lexington MA
Takeda Pharmaceuticals U S A Inc Lexington MA
The Central Nebraska Myeloma Support Group Grand Island NE
University Medical Center Hamburg Eppendorf Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003973
- 003
- CZ-PrNML
- 005
- 20230425141021.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2022.12.003 $2 doi
- 035 __
- $a (PubMed)36641358
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Thompson, Michael A $u Aurora Cancer Care, Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI,. Electronic address: michael.thompson@tempus.com
- 245 10
- $a Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients / $c MA. Thompson, M. Boccadoro, X. Leleu, J. Vela-Ojeda, F. van Rhee, KC. Weisel, RM. Rifkin, SZ. Usmani, R. Hájek, G. Cook, R. Abonour, M. Armour, KE. Morgan, SP. Yeh, CL. Costello, JG. Berdeja, FE. Davies, JA. Zonder, HC. Lee, J. Omel, A. Spencer, E. Terpos, VTM. Hungria, N. Puig, C. Fu, RH. Ferrari, K. Ren, DM. Stull, A. Chari
- 520 9_
- $a BACKGROUND: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM. MATERIALS AND METHODS: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019. RESULTS: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV. CONCLUSION: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www. CLINICALTRIALS: gov as #NCT02761187.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $7 D009101
- 650 12
- $a chřipka lidská $x prevence a kontrola $7 D007251
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a hospitalizace $7 D006760
- 650 _2
- $a vakcinace $7 D014611
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Boccadoro, Mario $u Division of Hematology, University of Torino, Torino, Italy
- 700 1_
- $a Leleu, Xavier $u Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France
- 700 1_
- $a Vela-Ojeda, Jorge $u Department of Hematology, UMAE Hospital de Especialidades Centro Medico La Raza IMSS, Mexico City, Mexico
- 700 1_
- $a van Rhee, Frits $u University of Arkansas for Medical Sciences, Little Rock, AR
- 700 1_
- $a Weisel, Katja C $u University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Rifkin, Robert M $u Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO
- 700 1_
- $a Usmani, Saad Z $u Levine Cancer Institute, Charlotte, NC
- 700 1_
- $a Hájek, Roman $u Department of Hemato-oncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Cook, Gordon $u Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK
- 700 1_
- $a Abonour, Rafat $u Indiana University School of Medicine, Indianapolis, IN
- 700 1_
- $a Armour, Mira $u Mijelom CRO, Croatian Myeloma Support Association, Zagreb, Croatia
- 700 1_
- $a Morgan, Kathryn E $u Myeloma Patients Europe, Brussels, Belgium
- 700 1_
- $a Yeh, Su-Peng $u China Medical University Hospital, Taichung City, P.R.China
- 700 1_
- $a Costello, Caitlin L $u University of California San Diego, La Jolla, CA
- 700 1_
- $a Berdeja, Jesus G $u Department of Hematology, Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN
- 700 1_
- $a Davies, Faith E $u Perlmutter Cancer Center, NYU Langone, New York, NY
- 700 1_
- $a Zonder, Jeffrey A $u Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI
- 700 1_
- $a Lee, Hans C $u Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
- 700 1_
- $a Omel, Jim $u The Central Nebraska Myeloma Support Group, Grand Island, NE
- 700 1_
- $a Spencer, Andrew $u Malignant Haematology and Stem Cell Transplantation Service, Alfred Health Monash University, Melbourne, Australia
- 700 1_
- $a Terpos, Evangelos $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
- 700 1_
- $a Hungria, Vania T M $u Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil
- 700 1_
- $a Puig, Noemi $u Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
- 700 1_
- $a Fu, Chengcheng $u First Affiliated Hospital, Soochow University, Suzhou Jiangsu, P.R.China
- 700 1_
- $a Ferrari, Renda H $u Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
- 700 1_
- $a Ren, Kaili $u Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
- 700 1_
- $a Stull, Dawn Marie $u Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
- 700 1_
- $a Chari, Ajai $u Department of Hematology-Oncology, Mount Sinai School of Medicine, New York, NY
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 23, č. 3 (2023), s. e171-e181
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36641358 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141018 $b ABA008
- 999 __
- $a ok $b bmc $g 1924563 $s 1190182
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 3 $d e171-e181 $e 20221207 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- LZP __
- $a Pubmed-20230418
